Form 4: Natera CFO Vests 59,596 Shares from RSU Award

Natera's Chief Financial Officer, Michael Burkes Brophy, vested 59,596 shares of common stock on January 14, 2026, as part of a pre-planned performance-based Restricted Stock Unit award.

Summary

• Michael Burkes Brophy, Natera's Chief Financial Officer, acquired 59,596 shares of Natera, Inc. common stock.
• The acquisition occurred on January 14, 2026, at a price of $0 per share, indicating a non-cash compensation event.
• This transaction represents the vesting of a performance-based Restricted Stock Unit (RSU) award that was originally granted on January 27, 2023.
• The vesting was triggered by the certification of a performance threshold related to one milestone under the RSU award.
• Following this transaction, Mr. Brophy beneficially owns a total of 123,722 shares of Natera common stock directly.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating it was a pre-arranged trading plan.

Sentiment

Score: 7

Explanation: The vesting of performance-based RSUs is a positive indicator of achieved business milestones and aligns executive interests with shareholders. It's a routine compensation event but reflects successful performance.

Positives

• The vesting of performance-based RSUs indicates that specific business performance criteria and milestones have been met, which is generally a positive sign for the company's operational execution.
• Increased direct ownership by a key executive (CFO) through vesting aligns management's interests with those of shareholders, fostering long-term value creation.

Future Outlook

The filing indicates that the RSU award vests in tranches upon the achievement of milestones relating to a combination of the passage of time and certain business performance criteria, suggesting ongoing performance targets for future vesting events.

Industry Context

The vesting of performance-based RSUs is a common practice in the biotechnology and diagnostics industry (where Natera operates) to incentivize executive performance and align interests with long-term company success. This type of compensation structure is standard for retaining key talent and driving strategic objectives.

Comparison to Industry Standards

• Performance-based RSU awards are a standard component of executive compensation packages across the biotech and healthcare sectors, similar to companies like Illumina, Guardant Health, or Exact Sciences.
• The vesting of 59,596 shares for a CFO is a significant equity grant, comparable to typical executive compensation structures in companies of similar market capitalization and growth stage.
• The use of Rule 10b5-1 plans for such transactions is also a common best practice for insiders to manage their equity holdings in a compliant and pre-scheduled manner, reducing concerns about insider trading.

Stakeholder Impact

• Shareholders: Positive, as it indicates achievement of performance milestones and increased alignment of the CFO's interests with shareholder value.
• Employees: May signal a positive internal environment where performance goals are being met.
• Management: The vesting serves as a reward for achieving performance targets and incentivizes continued strong performance.

Next Steps

• Future tranches of the RSU award will vest upon the achievement of additional milestones related to time and business performance criteria.

Key Dates

Recommendation

This Form 4 filing reports a routine, pre-planned vesting of performance-based Restricted Stock Units for a key executive. While it indicates the achievement of internal performance milestones, it does not present new information that would fundamentally alter the investment thesis for Natera. It reinforces management's alignment but doesn't provide a catalyst for a 'buy' or 'sell' recommendation based solely on this filing. Investors should continue to hold and monitor broader company performance and market trends.

Keywords

Natera, NTRA, Form 4, SEC filing, Restricted Stock Units, RSU vesting, insider ownership, CFO, Michael Burkes Brophy, equity compensation, performance-based award, Rule 10b5-1